24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects.

University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece.
Ophthalmology (Impact Factor: 6.17). 05/2005; 112(4):603-8. DOI: 10.1016/j.ophtha.2004.11.032
Source: PubMed

ABSTRACT To evaluate the 24-hour efficacy of brimonidine purite versus dorzolamide, each added to latanoprost.
Double-masked, 2-center, prospective, crossover comparison.
Primary open-angle glaucoma (POAG) subjects.
Subjects were randomized to brimonidine purite or dorzolamide, each given twice daily, for the first 6-week treatment period after a 6-week latanoprost run-in. Subjects began the opposite treatment for the second 6-week period after a 6-week latanoprost-only treatment between periods. Intraocular pressure (IOP) was measured at 8 am, 12 pm, 4 pm, 8 pm, 12 am, 4 am, and 8 am at each baseline and at the end of each treatment period. This study provided an 80% power that a 1.5-mmHg difference could be excluded between groups if 27 subjects completed the study. A standard deviation (SD) of 2.8 mmHg was assumed.
Twenty-four-hour efficacy of intraocular pressures of brimonidine purite versus dorzolamide, each added to latanoprost.
In 31 completed subjects, the baseline mean diurnal 24-hour IOP (+/- SD) was 19.0+/-1.7 mmHg for brimonidine purite and 19.0+/-1.6 mmHg for dorzolamide (P = 0.52). The 8 am IOP after 6 weeks of therapy was 18.4+/-2.1 mmHg for brimonidine purite and 18.9+/-1.9 mmHg for dorzolamide (P = 0.40). The mean diurnal IOP was 16.9+/-1.5 mmHg for brimonidine purite and 16.8+/-1.5 mmHg for dorzolamide (P = 0.66). Dorzolamide caused a more bitter taste (P = 0.01) than brimonidine purite.
This study suggests that brimonidine purite and dorzolamide, added to latanoprost, have similar efficacy and safety in POAG or ocular hypertensive subjects.

Download full-text


Available from: Constantinos H Karabatsas, Sep 29, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Glaucoma is a group of optic neuropathies characterized by retinal ganglion cell death, irreversible optic nerve damage, and vision loss. The treatment of glaucoma consists of reducing intraocular pressure (IOP) to a target level that is presumed to prevent further optic nerve deterioration. This presumption of clinical stability should be reevaluated at each clinical encounter with the patient and a new lower target IOP level estimated if progression has occurred.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To analyse 24 hour variations in intraocular pressure (IOP) and central corneal thickness (CCT) in a group of glaucomatous patients. 30 patients with primary open angle glaucoma were hospitalised and underwent circadian evaluations (at 8 pm, midnight, 4 am, 8 am, noon, and 4 pm) of supine and sitting IOP, respectively, measured using a Perkins and a Goldmann tonometer, and CCT measured using an ultrasonic pachymeter (the mean value of three measurements within 5 mum). All patients were treated with timolol 0.5% twice daily and latanoprost 0.005% once daily. Mean supine IOP was 15.3 (SD 3.7) mm Hg (range 10-25), with circadian fluctuations of 7.3 (3.3) mm Hg. Mean sitting IOP was 15.1 (3.9) mm Hg (range 8-26), with circadian fluctuations of 5.4 (3.1) mm Hg. Mean CCT was 534 (39) microm (range 443-637 microm) with circadian fluctuations of 16.5 (6.2) microm (range 6-31 microm). Both the within patient and within time point fluctuations in CCT were statistically significant (p<0.0001, ANOVA). The authors found considerable fluctuations in 24 hour IOP. The circadian fluctuations in CCT were small and, although statistically significant, did not seem to interfere with the circadian IOP assessment.
    British Journal of Ophthalmology 02/2006; 90(1):24-8. DOI:10.1136/bjo.2005.079285 · 2.81 Impact Factor
  • Drugs & Aging 02/2006; 23(9):762-3. · 2.50 Impact Factor